Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
Hydrogels are biocompatible drug delivery systems by which the physical properties can be controlled by the cross-linking density. Hydrogels were prepared by copolymerization of acrylic acid monomers in the presence of poly(ethylene glycol)(PEG) to form polyethylene diacrylate (PEDGA). Various molecular weights of PEGs were used for the synthesis of PEGDA to study the effect of molecular weight of PEG on the properties of hydrogels. These hydrogels were further characterized for free water, swelling..


Pharmaceutical Technology


A small burst release initially was observed from all the formulations, approximately 3–4% of the loaded drug was released during the first hour, which may have resulted from the adsorption of some of the drug molecules on the surface of the hydrogels. In the later phase, the release of the drug in the hydrogel matrix was assisted by the diffusion of water through the matrix. The release rate, therefore, decreased after the initial burst release because diffusion through the cross-linked polymer matrices is a time-consuming phenomenon. In each case, however, the release rate was faster for hydrogels made of higher molecular weight PEG, which might be as a result of the decrease in cross-linking density with the increase in molecular weight as the molar composition of PEGDA decreases for the same weight composition. The release rate is slower for higher molar percentages of PEGDA. As with the increase in hydrophilicity, the ease of drug release decreases because the drug diffuses out along with water as solution. For example, after 96 h, 80.38% of the loaded drug was released from B60 whereas 33.23% diclofenac was released from formulation D60 .


Table IV (a): Cumulative percentage of drug released by various hydrogel formulations.

Table IV (b): Cumulative percentage of drug released by various hydrogel formulations.









Drug release from matrix systems generally takes place by diffusion. As the diffusion of water in the present case increased with an increase in molecular weight of PEGDA (as found by the diffusion coefficient studies), the drug-release profile also followed similar trends (see Tables IV[a]) and IV [b]) as the drug was released from the hydrogels in the form of an aqueous solution. In the case of the same weight percentage of PEGDA, an increase in the molecular weight of PEGDA led to an increase in the release rate. For example, after 96 h, 35.24% of the loaded drug was released from B10 , whereas 59.35% diclofenac was released from formulation B40 within the same time period.

The data of release profiles for each formulation further were analyzed by model fitting using the following equations:












Table V: Results of data-fitting analysis of release profiles of the hydrogel formulations.
in which, % R is the percent of drug release; K is the release rate constant; t is the time of release; and e is the logarithmic exponent.


ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here